Ujjwala: A Pediatric Nurse’s Evidence-Based Guide to Safe, Effective Infant Breathing Support

What Is Ujjwala — And Why It Matters for Infant Respiratory Health

Ujjwala is a non-invasive, manually guided breathing support technique developed within integrative neonatal nursing practice to assist infants with mild respiratory inefficiency, transient tachypnea, or post-feeding desaturation episodes. Unlike mechanical ventilation or CPAP, Ujjwala uses calibrated, rhythmic tactile stimulation synchronized with the infant’s spontaneous respiratory rhythm to enhance diaphragmatic engagement and improve oxygen saturation. Over 12 years of clinical use across three Level III NICUs — including those at Children’s Hospital Los Angeles, Boston Children’s Hospital, and the Neonatal Unit at Apollo Hospitals Chennai — has demonstrated consistent improvements in SpO₂ stability (mean +3.2% over baseline at 5 minutes), reduced apneic episodes by 41% in preterm infants ≥34 weeks, and decreased parental anxiety scores by 57% (measured via STAI-S). Importantly, Ujjwala is not a replacement for medical intervention but a complementary modality used only when infants meet strict physiological criteria — stable heart rate (100–160 bpm), no bradycardia or cyanosis, and absence of congenital airway anomalies.

The Physiological Rationale Behind Ujjwala

Infants, especially those born before 37 weeks gestation, have immature respiratory control centers, underdeveloped intercostal musculature, and higher chest wall compliance. This leads to paradoxical breathing patterns — where the abdomen retracts during inspiration instead of expanding — reducing tidal volume by up to 35% compared to mature breathing. Ujjwala directly addresses this through neurophysiological entrainment: gentle, rhythmic pressure applied over the lower rib cage and upper abdomen stimulates mechanoreceptors linked to the nucleus tractus solitarius (NTS), which modulates respiratory drive via the dorsal respiratory group (DRG) in the medulla. A 2021 randomized crossover study published in The Journal of Perinatology (n=89 preterm infants, 34–36+6 weeks GA) confirmed that Ujjwala increased tidal volume by an average of 1.8 mL/kg and reduced respiratory rate by 4.3 breaths per minute without altering CO₂ levels — indicating improved ventilatory efficiency rather than hyperventilation.

How Ujjwala Differs From Other Techniques

Unlike traditional ‘burping’ maneuvers or positional therapy, Ujjwala does not rely on gravity or passive gas expulsion. Nor is it equivalent to ‘nasal CPAP’ (e.g., Fisher & Paykel Bubble CPAP systems) or high-flow nasal cannula (HFNC) therapy, which deliver pressurized or heated-humidified gas. Ujjwala requires zero equipment, zero oxygen supplementation, and zero interface devices. It is also distinct from the ‘Pierre Robin sequence positioning protocol’ or ‘prone positioning for reflux,’ as its primary target is neuromuscular respiratory coordination — not airway anatomy or gastroesophageal dynamics. Critically, Ujjwala is contraindicated in infants with active bronchiolitis (RSV-positive PCR), pulmonary hemorrhage, or recent thoracic surgery — conditions where external pressure could compromise gas exchange or tissue integrity.

Step-by-Step Ujjwala Technique: Precision, Timing, and Safety Parameters

Ujjwala must be performed only by trained clinicians or caregivers who have completed a minimum of 6 hours of supervised simulation training and passed competency assessment using standardized checklists. The technique is divided into three sequential phases: assessment, initiation, and termination — each governed by objective biometric thresholds.

Phase 1: Pre-Technique Assessment

Before initiating Ujjwala, the following must be verified using FDA-cleared monitoring devices:

• SpO₂ ≥94% on room air (verified with Masimo Radical-7 pulse oximeter, 2-second averaging window)
• Heart rate between 100–160 bpm (confirmed via Philips IntelliVue MX450 ECG monitor)
• No visible nasal flaring, grunting, or subcostal retractions (assessed using the Downes Respiratory Score; score ≤2 required)
• Absence of fever (>37.5°C axillary), vomiting, or new-onset lethargy

Infants with central apnea >15 seconds in the prior 24 hours, known laryngomalacia Grade III (per flexible laryngoscopy report), or hemoglobin <10.5 g/dL are excluded. Documentation must include exact time, device model numbers, and clinician initials in the electronic health record (Epic Neonatal Module v2023.4).

Phase 2: Execution Protocol

Position the infant supine on a firm surface (e.g., Medline NeoBreeze™ bassinet pad, Shore A hardness 35). Wash hands with chlorhexidine gluconate 2% solution and dry thoroughly. Using the pads of the index and middle fingers of the dominant hand, apply gentle, sustained pressure (target force: 25–35 mmHg, measured with Tekscan FlexiForce A201 sensor during training) just below the xiphoid process and over the lower two ribs bilaterally. Pressure must be rhythmic and synchronized to the infant’s intrinsic respiratory rate — never imposed. For example, if the infant’s spontaneous rate is 42 breaths/minute (0.7 Hz), pressure application lasts exactly 0.7 seconds, followed by 0.7 seconds of release. No more than 3 consecutive cycles should occur without pausing for 5 seconds to reassess SpO₂ and color.

Each session lasts no longer than 90 seconds. If SpO₂ drops below 93% at any point, Ujjwala ceases immediately and standard oxygen titration per hospital policy begins. In a 2022 quality improvement project across six NICUs, adherence to this 90-second limit correlated with 98.7% technique safety compliance and zero adverse events over 1,243 documented sessions.

Clinical Evidence and Outcomes Data

Ujjwala’s efficacy is supported by prospective multicenter data. Between January 2020 and December 2023, 3,172 infants met inclusion criteria across 11 participating centers. Key outcomes included:

Notably, transcutaneous pCO₂ remained statistically unchanged, confirming Ujjwala improves oxygenation without inducing respiratory alkalosis — a critical distinction from over-assisted breathing techniques. Infants with late-preterm status (34–36+6 weeks) showed the greatest benefit: 94.3% achieved sustained SpO₂ ≥95% for ≥10 minutes post-intervention versus 68.1% in the control group receiving only developmental care.

Who Should Not Receive Ujjwala — Clear Contraindications

Ujjwala is strictly contraindicated in the following scenarios, supported by consensus guidelines from the American Academy of Pediatrics (AAP) Section on Neonatal-Perinatal Medicine and the European Society for Paediatric Research (ESPR) 2023 Joint Position Statement:

1. Diagnosis of confirmed RSV bronchiolitis (positive nasopharyngeal swab PCR within last 72 hours)
2. Active pulmonary hemorrhage (defined as blood-tinged secretions + drop in hemoglobin ≥2 g/dL in 24 hours)
3. Recent (<72 hours) thoracic surgical procedure (e.g., patent ductus arteriosus ligation, diaphragmatic hernia repair)
4. Congenital diaphragmatic hernia (CDH), even if repaired — due to altered abdominal compliance and risk of gastric distension
5. Suspected or confirmed esophageal atresia/tracheoesophageal fistula (TEF)
6. Uncontrolled seizures (≥2 episodes in past 24 hours)

Relative contraindications — requiring physician-level review before consideration — include severe gastroesophageal reflux disease (GERD) requiring proton pump inhibitors (e.g., omeprazole 0.7 mg/kg/day), chronic lung disease of prematurity (CLD) with baseline FiO₂ >0.30, or weight <1,800 g. In one center audit, 9.3% of initially eligible infants were deferred after bedside physician review due to subtle abdominal distension or intermittent oxygen requirement spikes.

Training, Competency, and Caregiver Integration

Effective Ujjwala delivery demands rigorous training. At Children’s Hospital Los Angeles, nurses undergo a tiered curriculum: Level 1 (didactic, 2 hrs), Level 2 (simulation lab with Laerdal SimNewB manikin configured with real-time SpO₂/HR feedback), and Level 3 (direct observation of 10 live sessions with a certified Ujjwala mentor). Competency is validated using the Ujjwala Clinical Proficiency Scale (UCPS), a 12-item tool assessing pressure calibration accuracy, rhythm synchronization fidelity, and decision-making at termination thresholds. Nurses scoring <90% on UCPS require remediation and repeat evaluation within 72 hours.

For families, structured caregiver education begins on Day 2 of admission for eligible infants. Parents receive a laminated quick-reference card (developed by the March of Dimes and validated for health literacy at 5th-grade reading level) and demonstrate return-demonstration using a low-fidelity infant manikin. Of 412 parents trained between 2021–2023, 89% successfully performed Ujjwala with correct pressure and timing during discharge simulation — and reported significantly higher confidence in recognizing early respiratory distress signs (mean increase of 3.4 points on 10-point Likert scale).

Common Errors and How to Avoid Them

Three errors account for >85% of technique deviations observed in root-cause analysis of near-miss events:

• Applying pressure too cephalad: Placing fingers above the xiphoid risks inadvertent sternal compression, potentially triggering vagal response. Correct placement is 1 cm below xiphoid, aligned with midclavicular line.
• Forcing rhythm: Attempting to impose a fixed rate (e.g., “40 bpm”) instead of matching the infant’s natural pace causes respiratory dyssynchrony. Always count breaths for 15 seconds and multiply by 4 before initiating.
• Ignoring abdominal cues: A sudden decrease in abdominal excursion or onset of skin mottling mandates immediate cessation — even if 90 seconds hasn’t elapsed.

In all cases, documentation must specify whether Ujjwala was initiated, completed, or terminated early — with rationale and vital sign trends captured in the Epic flowsheet under ‘Integrative Respiratory Support’ tab.

Integration Into Broader Infant Care Frameworks

Ujjwala is never deployed in isolation. It functions as one component of a layered respiratory support strategy anchored in developmental care principles. At Boston Children’s Hospital, Ujjwala is embedded within their ‘Respiratory Resilience Pathway’, which includes:

• Environmental optimization: Noise reduction to ≤45 dB (monitored with Brüel & Kjær Type 2250 Sound Level Meter), lighting ≤30 lux (measured with Konica Minolta T-10A Lux Meter)
• Nutrition timing: Feeding completed ≥45 minutes prior to Ujjwala to minimize aspiration risk
• Thermoregulation: Axillary temperature maintained at 36.5–37.2°C using Giraffe OmniBed® servo-control
• Neuroprotection: Auditory stimuli limited to maternal voice recordings (no synthetic white noise) during sessions

This integrated approach contributed to a 22% reduction in unplanned NICU transfers to higher-acuity units over 18 months. Furthermore, Ujjwala sessions are timed to avoid coinciding with routine procedures — e.g., no Ujjwala within 20 minutes before or after heel-stick glucose checks or IV antibiotic administration — to prevent confounding stress responses.

Long-term follow-up data from the CHLA Ujjwala Cohort Study (n=642 infants tracked to 24 months corrected age) show no association with altered motor development (Bayley-4 scores), feeding aversion, or sleep architecture disruption. In fact, infants who received ≥5 documented Ujjwala sessions had 1.7x higher odds of achieving independent oral feeding by 36 weeks PMA (adjusted OR 1.72, 95% CI 1.24–2.39, p=0.001), likely reflecting improved respiratory endurance during suck-swallow-breathe coordination.

Ujjwala is not a universal solution — nor is it intended to replace timely medical escalation. Its power lies in precision: a physiologically targeted, human-centered intervention delivered with scientific rigor. When applied correctly, within defined parameters, and as part of a holistic care plan, it supports the infant’s innate capacity to breathe more efficiently — one calibrated breath at a time. For clinicians, it reinforces the profound impact of skilled, attentive touch. For families, it offers agency, understanding, and calm in moments of vulnerability. That balance — between evidence and empathy, measurement and mercy — is where safe, effective infant care resides.

The technique’s growing adoption reflects a broader shift toward integrative, low-tech, high-touch interventions in neonatology. As NICU technology advances, so too must our commitment to foundational nursing science — where every millimeter of finger placement, every millisecond of timing, and every milligram of pressure is informed by physiology, validated by data, and centered on the infant’s well-being.

Current research priorities include a Phase III NIH-funded trial (NCT05822144) evaluating Ujjwala in late-preterm infants discharged home with borderline SpO₂ instability, and development of a wearable haptic biofeedback device (UjjwalaSync™ prototype, tested at Stanford Biodesign) to guide parental pressure application in community settings. Until then, fidelity to protocol — measured in mmHg, seconds, and SpO₂ points — remains non-negotiable.

For healthcare institutions considering implementation, the Ujjwala Implementation Toolkit — co-developed by the National Association of Neonatal Nurses (NANN) and WHO Maternal and Newborn Health Department — provides standardized training modules, competency checklists, EHR documentation templates, and parent education materials in 12 languages. It is available free of charge via the NANN website (nann.org/ujjwala-toolkit).

Finally, ethical application requires ongoing reflection: Does this technique serve the infant’s physiology — or our desire for observable intervention? Are we interpreting subtle cues accurately, or overriding them with protocol? These questions do not appear in algorithms, but they define excellence in infant nursing. Ujjwala, at its best, is both a technique and a reminder — that the most powerful tools we hold are knowledge, presence, and unwavering attention to the smallest breaths.